Author: Newsdesk

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Better Choice Company, Inc. (OTCQB: BTTR) (the “Company” or “Better Choice”), an animal health and wellness company, today reported its financial results for the third quarter ended September 30, 2020.

“We are very excited to share our third quarter 2020 results with the investor community. 2020 has been a “banner year” for Better Choice and we are excited to be a leader in the highest growth areas of the pet food industry as we move into 2021,” said Werner von Pein, CEO of Better Choice.

“We have a strong presence in the highest growth segments of animal health with e-commerce and direct-to-consumer sales representing ~60% of consolidated revenue,” continued Mr. von Pein. “We are uniquely positioned to benefit in the current global environment as consumers move online and we are focused on continuing to convert a large number of our customer base into “sticky” subscription or recurring revenue purchasers. Our international expansion continues to accelerate and represented 27% and 22% of net sales for Q3 and year-to-date, respectively. A strong internal focus on achieving cash flow positivity, managing costs and adopting industry best practices provides a strong foundation for us as we execute on organic growth and evaluate M&A opportunities, with both avenues presenting compelling expansion opportunities.”

Operational Update
s

• Continued to grow the business throughout the COVID-19 recession, primarily in e-commerce, direct-to-consumer and international (sold through domestic distributors).
• Successfully integrating the TruPet and Halo subsidiaries.
• Received approval in June 2020 from the Chinese Ministry of Agriculture to ship 15 diets directly to mainland China. Net sales in China were $1.8mm and $3.5mm for Q3 and year to date, respectively, and expect annual revenue in China to be ~$7mm and growing. We expect total international annual revenue to be ~$12mm.
• Consolidated warehouse operations in October 2020 into one location, just outside of Nashville, TN.
• Raised more than $20mm of equity in October 2020 to support growth and de-lever the balance sheet, including more than $11mm invested by Company insiders.

Financial Results for the
Third
Quarter
and
Year-to-
Date
2020

• Year-to-date 2020 Net Sales of $33.3mm
• Third quarter 2020 Net Sales of $11.1mm
• Year-to-date 2020 Loss from operations of $24.3mm
• Third quarter 2020 Loss from operations of $3.3mm
• Year-to-date 2020 Adjusted EBITDA of ($1.1mm)
• Third quarter 2020 Adjusted EBITDA of ($0.4mm)

Conference Call and Webcast Information

The Company will host a conference call and audio webcast on Wednesday, November 18 at 8:30 a.m. ET to answer questions about the Company’s operational and financial highlights for the third quarter of 2020.

Event:	Better Choice Third Quarter 2020 Financial Results Conference Call
Date:	Wednesday, November 18, 2020
Time:	8:30 a.m. Eastern Time
Live Call:	+1-877-407-4018 (U.S. Toll-Free) or +1-201-689-8471 (International)
Webcast:	http://public.viavid.com/index.php?id=142446

For interested individuals unable to join the conference call, a dial-in replay of the call will be available until September 1, 2020 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 13713159.

Better Choice Company Inc.

Condensed Consolidated
Statements of Operations and Comprehensive Loss

(unaudited)

(Dollars in thousands, except share and per share amounts)

	Nine Months Ended September 30,										Three Months Ended September 30,
	2020					2019					2020					2019
Net sales	$	33,302				$	11,567				$	11,135				$	3,932
Cost of goods sold	20,567					7,178					6,681					3,096
Gross profit	12,735					4,389					4,454					836
Operating expenses:
General and administrative	23,298					12,031					3,648					4,856
Share-based compensation	7,047					6,708					1,543					2,496
Sales and marketing	6,203					8,452					2,396					2,856
Customer service and warehousing	500					854					148					303
Total operating expenses	37,048					28,045					7,735					10,511
Loss from operations	(24,313		)			(23,656		)			(3,281		)			(9,675		)
Other expense (income):
Interest expense, net	7,268					165					2,537					41
Loss on extinguishment of debt	88					—					88					—
Loss on acquisitions	—					147,376					—					(2,612		)
Change in fair value of warrant derivative liability	(2,118		)			(886		)			(4,213		)			(1,079		)
Total other expense (income), net	5,238					146,655					(1,588		)			(3,650		)
Net and comprehensive loss	(29,551		)			(170,311		)			(1,693		)			(6,025		)
Preferred dividends	103					70					35					43
Net and comprehensive loss available to common stockholders	$	(29,654	)			$	(170,381	)			$	(1,728	)			$	(6,068	)
Weighted average number of shares outstanding, basic and diluted	48,809,740					28,624,230					48,961,447					43,575,010
Loss per share, basic and diluted	$	(0.61	)			$	(5.95	)			$	(0.04	)			$	(0.14	)

Non-GAAP Measures

Better Choice Company defines Adjusted EBITDA as EBITDA further adjusted to eliminate the impact of certain items that we do not consider indicative of our core operations. Adjusted EBITDA is determined by adding the following items to net and comprehensive loss: depreciation and amortization, interest expense, share-based compensation, warrant expense and dividends, change in fair value of warrant derivative liability, loss on extinguishment of debt, loss on acquisitions, acquisition related expenses, purchase accounting adjustments, equity and debt offering expenses and COVID-19 expenses.

The Company presents Adjusted EBITDA it is a key measure used by our management and board of directors to evaluate our operating performance, generate future operating plans and make strategic decisions regarding the allocation of capital. We believe that the disclosure of Adjusted EBITDA is useful to investors as this non-GAAP measure forms the basis of how our management team reviews and considers our operating results. By disclosing this non-GAAP measure, we believe that we create for investors a greater understanding of and an enhanced level of transparency into the means by which our management team operates our company. We also believe this measure can assist investors in comparing our performance to that of other companies on a consistent basis without regard to certain items that do not directly affect our ongoing operating performance or cash flows.

Adjusted EBITDA does not represent cash flows from operations as defined by GAAP. Adjusted EBITDA has limitations as a financial measure and you should not consider it in isolation, or as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Because of these limitations, you should consider Adjusted EBITDA alongside other financial performance measures, including various cash flow metrics, net loss, gross margin, and our other GAAP results.

The following table presents a reconciliation of net and comprehensive loss, the closest GAAP financial measure, to EBITDA and Adjusted EBITDA for each of the periods indicated.

Better Choice Company Inc.
Reconciliation of Net Loss to EBITDA, Adjusted EBITDA and Pro Forma Adjusted EBITDA
	Nine Months Ended				Three Months Ended				Three Months Ended				Three Months Ended
	September 30,				September 30,				June 30,				March 31,
		2020				2020				2020				2020
Net and comprehensive loss	$	(29,654	)		$	(1,728	)		$	(18,438	)		$	(9,488	)
Depreciation and amortization		1,298				432				409				457
Interest expense, net		7,268				2,537				2,430				2,301
EBITDA		(21,088	)			1,241				(15,599	)			(6,730	)
Non-cash share-based compensation(a)		7,047				1,543				3,020				2,484
Non-cash warrant expense(b)		9,986				–				7,390				2,594
Non-cash dividends(c )		103				34				34				35
Non-cash change in fair value of warrant derivative liability		(2,118	)			(4,213	)			3,474				(1,379	)
Loss on extinguishment of debt		88				88				–				–
Acquisition related expenses/(income)(d)		1,236				(57	)			616				677
Non-cash effect of purchase accounting on cost of goods sold(e)		894				–				–				894
Offering relating expenses(f)		987				338				334				315
Non-recurring expenses(g)		1,719				658				79				982
COVID-19 expenses(h)		30				5				25				–
Adjusted EBITDA	$	(1,117	)		$	(362	)		$	(627	)		$	(128	)
(a) Reflects non-cash expenses related to equity compensation awards. Share-based compensation is an important part of the Company’s compensation strategy and without our equity compensation plans, it is probable that salaries and other compensation related costs would be higher.
(b) Reflects non-cash expenses related to stock purchase warrants associated with a contract that was subsequently terminated.
(c) Reflects non-cash expenses related dividends that were settled in October 2020 in connection with the issuance of Series F preferred stock.
(d) Reflects costs incurred related to acquisition and integration activities that will not recur and operating expenses that will not recur due to acquisition related synergies.
(e) Reflects non-cash expense recognized in cost of goods sold related to the step-up of inventory required under the accounting rules for business combinations.
(f) Reflects administrative costs associated with the registration of previously issued common shares and other debt and equity financing transactions.
(g) Reflects contract termination costs and the write off of a prepaid asset related to the termination of a contract entered into during 2019, including $0.8 million and $0.4 million of non-cash expenses, respectively, for the nine month period; and other non-recurring costs.
(h) Reflects cleaning, sanitizing, protective equipment and hazard compensation related to COVID-19.

During October 2020, we completed the outsourcing of certain warehouse operations to a third party logistics facility. We expect that this operational improvement would have provided approximately $0.3mm in cost savings for the year-to-date period had it been implemented on January 1, 2020.

About Better Choice Company, Inc.

Better Choice Company Inc. is a rapidly growing animal health and wellness company committed to leading the industry shift toward pet products and services that help dogs and cats live healthier, happier and longer lives. We take an alternative, nutrition-based approach to animal health relative to conventional dog and cat food offerings, and position our portfolio of brands to benefit from the mainstream trends of growing pet humanization and consumer focus on health and wellness. We have a demonstrated, multi-decade track record of success selling trusted animal health and wellness products, and leverage our established digital footprint to provide pet parents with the knowledge to make informed decisions about their pet’s health. We sell the majority of our dog food, cat food and treats under the Halo and TruDog brands, which are focused, respectively, on providing sustainably sourced kibble and canned food derived from real whole meat, and minimally processed raw-diet dog food and treats. For more information, please visit https://www.betterchoicecompany.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements may not be achieved. Further information on the Company’s risk factors is contained in our filings with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

Better Choice Company, Inc.
Werner von Pein, CEO

Investor Contact:

Red Chip Companies, Inc
Dave Gentry
407-491-4498
[email protected]

–Approval based on four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery–

–EXPAREL is the first long-acting non-opioid option for field block and brachial plexus or femoral nerve block approved in Europe–

PARSIPPANY, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NADSAQ: PCRX), the leading global provider of non-opioid pain management options, today announced that the European Commission has granted marketing authorization for EXPAREL as a brachial plexus block or femoral nerve block for treatment of post-operative pain in adults, and as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds in adults.

“We are pleased to see news of the European Commission’s approval of EXPAREL and look forward to the opportunity to bring a safe and effective opioid alternative to surgical patients across Europe,” said Dave Stack, Chief Executive Officer and Chairman of Pacira BioSciences. “Europe has long been at the forefront of enhanced recovery after surgery – or ERAS – models of care. With the European Commission’s broad approval for EXPAREL across a wide variety of surgical settings and administration techniques, we see a well-defined position for EXPAREL to play an integral role in further optimizing postsurgical protocols and accelerating postoperative recovery.”

The European Commission approval was based on the results of four pivotal Phase 3 studies that demonstrated improvements in pain reduction and opioid use. These studies include:

• Lower Extremity
  Nerve Block
  Study: This study assessed the safety and efficacy of EXPAREL as a femoral nerve block in patients undergoing total knee arthroplasty. Results demonstrated that EXPAREL resulted in a significant reduction in cumulative pain scores over 72 hours compared to placebo. A higher percentage of patients who received EXPAREL were pain-free, consumed fewer opioids and reported higher satisfaction with their pain control compared with placebo.
• Upper Extremity
  Nerve Block
  Study: This study assessed the safety and efficacy of EXPAREL as an interscalene brachial plexus nerve block in patients undergoing total shoulder arthroplasty or rotator cuff repair. Results demonstrated that EXPAREL significantly improved pain control and reduced opioid consumption through 48 hours compared with placebo and a standardized pain management protocol alone.
• Hard Tissue
  Infiltration
  Study: This study assessed the safety and efficacy of EXPAREL administered via infiltration in patients undergoing bunionectomy. Results demonstrated that EXPAREL significantly reduced pain and opioid consumption compared with placebo over the first 24 hours following surgery than patients administered placebo.
• Soft Tissue
  Infiltration
  Study: This study assessed the safety and efficacy of EXPAREL administered via infiltration in patients undergoing hemorrhoidectomy. Results demonstrated that EXPAREL significantly reduced pain compared to placebo at all time points, including a 30 percent reduction in the cumulative pain scores at 72 hours. Patients who received EXPAREL consumed significantly fewer opioids than patients administered placebo.

The European Commission decision is applicable to all 27 European Union member states plus the United Kingdom, Iceland, Norway and Liechtenstein. Commercial planning is underway, with an anticipated launch in the second half of 2021. EXPAREL was initially approved in the United States for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Since its launch, EXPAREL has been used in over seven and a half million patients.

About
Pacira
BioSciences

Pacira BioSciences, Inc. is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL^® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam^®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera° system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

About EXPAREL

EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. The product combines bupivacaine with DepoFoam^®, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.

Important Safety Information for Patients

EXPAREL should not be used in obstetrical paracervical block anesthesia. In studies where EXPAREL was injected into the wound, the most common side effects were nausea, constipation, and vomiting. In studies where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, and constipation. EXPAREL is not recommended to be used in patients younger than 18 years old or in pregnant women. Tell your healthcare provider if you have liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is eliminated from your body. EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL: can affect your nervous system and your cardiovascular system; may cause an allergic reaction; may cause damage if injected into your joints.

Company Contact
s
:

Investors:

Susan Mesco, (973) 451-4030
Pacira BioSciences, Inc.
[email protected]

Media:

Alyssa Schneider, (973) 588-2270
Coyne Public Relations
[email protected]

SANTA CLARA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) — Applied Materials, Inc. announced today that Gary Dickerson, President and CEO, and Dan Durn, Senior Vice President and CFO, will participate in upcoming virtual investor conferences.

Mr. Dickerson will participate in a fireside chat at the Credit Suisse Technology Conference on Tuesday, Dec. 1 beginning at 9:10 a.m. PT / 12:10 p.m. ET.

On Wednesday, Dec. 2, Mr. Durn will participate in a fireside chat at the Nasdaq Virtual Investor Conference beginning at 8:30 a.m. PT / 11:30 a.m. ET and the Wells Fargo TMT Summit at 11:40 a.m. PT / 2:40 p.m. ET.

Mr. Durn will also participate in a fireside chat at the Barclays Global Technology, Media and Telecommunications Conference on Thursday, Dec. 10 beginning at 8:00 a.m. PT / 11:00 a.m. ET.

Live audio webcasts of these sessions will be available on the Applied Materials website at http://www.appliedmaterials.com/company/investor-relations and a replay of each event will be available on the same day.

About Applied Materials

Applied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions used to produce virtually every new chip and advanced display in the world. Our expertise in modifying materials at atomic levels and on an industrial scale enables customers to transform possibilities into reality. At Applied Materials, our innovations make possible the technology shaping the future. Learn more at www.appliedmaterials.com.

Contact:

Ricky Gradwohl (editorial/media) 408.235.4676
Michael Sullivan (financial community) 408.986.7977

TORONTO, Nov. 18, 2020 (GLOBE NEWSWIRE) — QuestCap Inc. (“QuestCap”) (NEO:QSC; OTC:COPRF; FRA:34C1) is pleased to announce the launch of a master license agreement between its wholly owned subsidiary, Collection Sites, LLC and Brixmor Property Group (NYSE: BRX), a real estate investment trust (REIT) that owns and operates a high-quality, national portfolio of open-air shopping centers with retailers including T.J. Maxx, Kroger, Wal-Mart, and L.A. Fitness, among others. Collection Sites will lease space in the parking lots of 340 shopping centers owned by Brixmor for an initial 6-month term with the option to extend.

“Based on the initial strong demand from the first 20 collection sites, we know Americans are looking for the convenient and effective COVID-19 testing solution that Collection Sites offers,” says Mr. Doug Sommerville, CEO of QuestCap, Inc. “We are pleased that our subsidiary is able to provide greater access to testing, where and when people need it. By making testing part of a regular shopping routine, we can combat this virus and help flatten the curve.”

With this agreement, a network of ‘pop-up’ COVID-19 testing sites will be rolled out across the United States. The pop-up labs will be managed by Las Vegas-based company Collection Sites, LLC and powered by Alcala Testing and Analysis Services, a CLIA-licensed laboratory based in San Diego, California. Appointments and payments will be handled through an online portal www.testbeforeyougo.com.

The network of pop-up labs will be located across 340 Brixmor locations in 32 U.S. states with California and Texas targeted initially. Testing sites will now be available for Americans seeking fast, available, and accurate testing for themselves and their loved ones in the weeks and months ahead. The first location is set to begin installation this month with daily testing capacity of 150 tests per site and charging USD $59 to $139 per test.

“Our shopping centers play a critical role in the communities we serve, providing access to essential retail services such as groceries, pharmacies and medical services,” said Howard Porter, senior vice president of specialty leasing for Brixmor. “Adding a much-needed service such as COVID-19 testing stations is just another meaningful way to use our conveniently located centers as community assets.”

QuestCap’s/Collection Sites’ real estate broker, Ryan Zickler of Zickler Associates LLC, also headquartered in Indiana, presented the concept to Brixmor as a means to serve their communities by providing a convenient location for COVID testing.  Zickler brokered the transaction and helped facilitate post lease execution logistics between the parties.

The key to flattening the curve is to increase testing.

The new testing centers will offer convenient access to rapid antibody and antigen (pending availability) tests – which take 8-10 minutes to administer and provide results within 24 hours. The sites also offer regular RT-PCR, with results within 24 hours of testing.  All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.

For more information about the pop-up lab, the available sites and services visit 

www.testbeforeyougo.com

.

About
Brixmor

Brixmor (NYSE: BRX) is a real estate investment trust (REIT) that owns and operates a high-quality, national portfolio of open-air shopping centers. Its 395 retail centers comprise approximately 69 million square feet of prime retail space in established trade areas. The Company strives to own and operate shopping centers that reflect Brixmor’s vision “to be the center of the communities we serve” and are home to a diverse mix of thriving national, regional and local retailers. Brixmor is a proud real estate partner to approximately 5,000 retailers including The TJX Companies, The Kroger Co., Publix Super Markets, Wal-Mart, Ross Stores and L.A. Fitness.

About
QuestCap
Inc.

QuestCap
Inc. (NEO:QSC; OTC:COPRF; FRA:34C1)  seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, QuestCap offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.

QuestCap has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space.   This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.

QuestCap’s primary focus is the sale of COVID-19 IgG/IgM antibody tests authorized by FDA under an EUA for use by authorized laboratories. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments will be handled through the online portal  www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.

For additional information, please contact:

Doug Sommerville, CEO
[email protected]
+1 416-301-5418

For investing inquiries please contact:
Evan Veryard
[email protected]

For US media enquires please contact:
Veronica Welch
[email protected]
+1-508-643-8000

Cautionary Note Regarding Forward-looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the agreement among Collection Sites LLC and Brixmor; the proposed roll-out of testing sites; projected timelines for testing results; projected revenues from the testing; the pursuit by QuestCap of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE NEO EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. 

TORONTO, Nov. 18, 2020 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce that the Company has been presented with the Deloitte’s Technology Fast 50™ program award (“Fast 50™”) for its rapid revenue growth, entrepreneurial spirit and bold innovation. The program recognizes Canada’s 50 fastest-growing technology companies with the highest revenue-growth percentage over the past four years. VitalHub ranks 10th on the Fast 50™ list with a 1995% growth in revenue from 2016 to 2019.

Fast 50 program winners consist of public and private companies in the technology sector, which have transformed the industry. Now in its 23rd year, the program runs alongside the broader Deloitte North American Technology Fast 500™, with winners automatically eligible for this elite ranking.

VitalHub’s CEO Dan Matlow credits the Company’s ability to respond swiftly and effectively to the evolving needs of healthcare systems globally and the ease of adoption of its turnkey solutions with the Company’s 1995% revenue growth. Matlow said, “We appreciate the continued and growing recognition of VitalHub as industry leaders, both nationally and abroad. We would like to acknowledge and thank our investors, our customers, and our employees— whose continued support has worked together to make this happen. We are excited to see that our growth strategy has yielded such positive results and look forward to continuing to execute on our plan toward our vision of being a global solutions leader.”

“This year’s Fast 50 winners should be especially proud of this designation, as their role in the fabric of Canadian business—particularly during these turbulent times—is crucial,” said Erica Pretorius, partner and national leader for the Technology Fast 50 program at Deloitte Canada. “Their bold vision and true commitment to innovation allow them to not only improve today’s world, but also shape tomorrow’s, despite the constant uncertainty. This year’s winners are proving themselves resilient, innovative and adaptable, all in an unpredictable year defined by economic instability and the continuing public health crisis.”

To qualify for the Deloitte Technology Fast 50 ranking, companies must have been in business for at least four years, have revenues of at least $5 million, be headquartered in Canada, own proprietary technology, conduct research and development activities in Canada and invest a minimum of five percent of gross revenues in R&D.

ABOUT THE DELOITTE TECHNOLOGY FAST 50™

The Deloitte Technology Fast 50 program is Canada’s pre-eminent technology awards program. Celebrating business growth, innovation and entrepreneurship, the program features distinct categories, including the Technology Fast 50 ranking, Enterprise Fast 15, and Companies-to-Watch. The program also recognizes companies within the North American Technology Fast 500 ranking, identifying technology companies in the United States and Canada. The 2020 program sponsors include Deloitte, RBC, CBRE, Clarity Recruitment, and Lafond. For further information, visit www.fast50.ca.

ABOUT DELOITTE

Deloitte provides audit and assurance, consulting, financial advisory, risk advisory, tax, and related services to public and private clients spanning multiple industries. Deloitte serves four out of five Fortune Global 500® companies through a globally connected network of member firms in more than 150 countries and territories bringing world-class capabilities, insights, and service to address clients’ most complex business challenges. Deloitte LLP, an Ontario limited liability partnership, is the Canadian member firm of Deloitte Touche Tohmatsu Limited. Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms.

Our global Purpose is making an impact that matters. At Deloitte Canada, that translates into building a better future by accelerating and expanding access to knowledge. We believe we can achieve this Purpose by living our shared values to lead the way, serve with integrity, take care of each other, foster inclusion, and collaborate for measurable impact.

To learn more about how Deloitte’s approximately 312,000 professionals, over 12,000 of whom are part of the Canadian firm, please connect with us on LinkedIn, Twitter, Instagram, or Facebook.

ABOUT VITALHUB

Software for Health and Human Services providers designed to simplify the user experience & optimize outcomes.

VitalHub provides technology to Health and Human Services providers including; Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services. VitalHub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination, Patient Flow & Operational Visibility, and DOCit Mobile Apps.

The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently, VitalHub serves 275+ clients across Canada, USA, UK, Australia, Qatar, and Latvia. VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The Company is publicly traded on the TSX Venture Exchange under the symbol “VHI”.

CAUTIONARY STATEMENT

This press release includes forward-looking statements regarding the Corporation and its business, which may include, but is not limited to, statements with respect to the appointment of a new directors. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the technology industry, failure to obtain regulatory or shareholder approvals, market conditions, economic factors, the equity markets generally and risks associated with growth and competition. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Corporation undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT INFORMATION

Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
[email protected]

Research Triangle Park, NC, Nov. 18, 2020 (GLOBE NEWSWIRE) — Get Spiffy, Inc. (SpiffyⓇ), an on-demand car care, technology, and services company, today announced the launch of Digital Servicing™ powered by Spiffy Dealer Solutions, a suite of resources designed to equip automotive dealerships for the next phase of the digital evolution: mobile digital servicing. Complete packages include a Dealer branded software platform for internal and customer-facing audiences, vans upfitted with proprietary designs for efficient and eco-friendly mobile services, and best practices training for managers and service technicians.

According to Cox Automotive’s Remimaging the Automotive Consumer Experience study, consumers indicated the most friction in automotive experience comes from routine servicing, with at-home maintenance listed as a top solution. The impacts of COVID-19 on top of existing consumer trends away from the dealership and towards convenience, have ushered in a new wave of digital innovation for service departments. Instead of expecting the customer to come to the dealership, Digital Servicing™ brings the dealership directly to the customer’s door – on their terms and with seamless communication via app or text message.

During the pandemic, 67 percent of dealerships implemented valet-based pickup and delivery, but only 59 percent continue to offer it. Those that do now struggle with the complexity and high costs of moving a customer’s car four times with two people involved in each leg. Spiffy’s innovative Digital Servicing solutions offer a comprehensive platform built over six years, with millions of dollars of investment and tens of thousands of engineering hours. Alternatively, dealerships can choose customized components to quickly and effectively ramp up for digital mobile servicing.

“Digital retailing was trending in the automotive industry with companies like Carvana making waves, and the pandemic rapidly accelerated the same trends for digital services. Now, more automotive service departments are starting to realize how mobile maintenance can expand revenue and create better customer experiences,” said Scot Wingo, Spiffy CEO. “Relationship-wise, it’s similar to how we view franchises. We provide the dealership with the resources to launch and operate a digital servicing arm of the business, directly at their customers’ doors.”

Each van is Dealer branded and upfitted for eco-conscious services via proprietary Spiffy Green™ technology, including power, water, and reclamation systems. Customization options include Electric Van and VanBrain™. Every mobile service provider can attend in-person and online training, while department managers can receive consulting to better target convenience-oriented consumers with on-demand maintenance. The heart of the package is world-class software to power a Dealer branded native iPhone and Android app suite including a consumer app, technician app, and manager/customer service dashboard, which simplifies appointments and delivers an unparalleled customer experience. 

“Developing a zero-friction consumer experience is a part of Spiffy’s DNA, and it’s exciting to project a future where our software platform can be a valuable resource throughout the automotive industry,” added Ryan Eade, CTO. “By integrating behind-the-scenes logistics for dealerships with convenient appointment scheduling and immediate digital billing for consumers, we’re able to provide the best for both parties.”

To learn more, visit getspiffy.com/dealer. 

About Spiffy

Spiffy® (www.getspiffy.com) is an on-demand technology and services company with the mission to disrupt the car care experience everywhere. Spiffy offers a variety of zero contact hand car washing, advanced detailing, and disinfection services for vehicles and facilities, in addition to oil change, tires, and other maintenance service options. Customers can schedule in less than two minutes with the Spiffy app. Every service is conveniently performed on-site at fleets, office parks, and residences using the Spiffy Green™ system that is the eco-friendliest way to service a vehicle.

Spiffy is available in cities and metro areas including Atlanta, Baltimore, Charlotte, Dallas-Fort Worth, Denver, Dover, Fort Lauderdale, Los Angeles, Las Vegas, Miami, New York, Orlando, Palm Springs, Philadelphia, Phoenix, Raleigh-Durham, San Diego, San Francisco, Seattle-Tacoma, St. Louis, Tampa, Tucson, and Washington DC. Customers everywhere can purchase Spiffy disinfection solutions at ​spiffydisinfectionstore.com​.

Attachment

• Spiffy-Digital-Servicing-Featured-Image

Grayson Leverenz
Get Spiffy, Inc.
919-500-2481
[email protected]

VANCOUVER, British Columbia, Nov. 18, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality for eCommerce, AR learning applications, AR-enhanced video conferencing and virtual events is pleased to announce that NexTech CEO, Evan Gappelberg, will be presenting at a special Proactive Investors Livestream focusing on NexTech and the innovative Augmented Reality solutions behind its triple-digit sales growth.

NexTech’s live presentation will take place at 1:00PM ET onThursday, November 19, 2020

Please click the link below to register for the Livestream:

CLICK TO REGISTER FOR LIVESTR




E




AM

Passcode: 519400

Evan will update investors on NexTech’s latest technological advances, the recent Q3 record revenue growth with Bookings of $6.7 million, +327% growth over Q3 2019 and the company’s progress as it pursues four multi-billion-dollar verticals in AR.

Q3 2020 Financial highlights:

• Total Bookings $6.7 million +327% growth over Q3 2019
• Record revenue grows 200% to $4.7 million
• Record backlog of $2 million
• Gross Profit grows 344% to $3.0 million with a 63% margin
• Working Capital of $13.6 million
• Full report has been filed and is available on SEDAR

Other Q3 Highlights:

• Filed to up-list its stock to NASDAQ Capital Market July 2^nd
• Hired Eugen Winschel 18-year SAP Executive as new COO
• Doubled the size of the company to 140 in Q3 from just 70 in Q2 – to continue to meet the rapid ramp up in demand and increase the company’s technological capabilities
• Company became approved Microsoft partner
• Launched new distribution deals with well-known consumer brands including Dyson, Philips Norelco, Mr. Coffee, VitaMix, Breviel and Cuisinart
• Landed $250,000 EdTech AR contract with Ryerson University
• Appointed Ori Inbar to its Board of Directors, a recognized AR expert, having been involved in the industry for over a decade as both a start-up entrepreneur and a venture capital investor through Super Ventures
• Acquired the assets of Next Level Ninjas for $720,000 cash consideration
• Launches “Screen AR” A New Augmented Reality Immersive Video Conferencing Software to Accelerate Business Opportunities
• Began building Collaborative Video Conferencing Capabilities to rival Zoom and address Telemedicine and EdTech Markets

The company has issued 500,000 3-year stock options exercisable at $7.24 to its employees under its stock option plan. Also, Felix Ritscher was issued 4,555 common shares with a standard 4-month restriction as a signing bonus.

About NexTech AR

NexTech is one of the leaders in the rapidly growing Augmented Reality market estimated to grow from USD $10.7B in 2019 and projected to reach USD $72.7B by 2024 according to Markets & Markets Research; it is expected to grow at a CAGR of 46.6% from 2019 to 2024.

The company is pursuing four verticals:

InfernoAR:
An advanced Augmented Reality and Video Learning Experience Platform for Events, is a SaaS video platform that integrates Interactive Video, Artificial Intelligence and Augmented Reality in one secure platform to allow enterprises the ability to create the world’s most engaging virtual event management and learning experiences. Automated closed captions and translations to over 64 languages. According to Grandview Research the global virtual events market in 2020 is $90B and expected to reach more than $400B by 2027, growing at a 23% CAGR. With NexTech’s InfernoAR platform having augmented reality, AI, end-to-end encryption and built in language translation for 64 languages, the company is well positioned to rapidly take market share as the growth accelerates globally.

ARitize™ For eCommerce:
The company launched its SaaS platform for webAR in eCommerce early in 2019. NexTech has a ​‘full funnel’ end-to-end eCommerce solution for the AR industry including its Aritize360 app for 3D product capture, 3D/AR ads, its ARitize white label app it’s ‘Try it On’ technology for online apparel, 3D and 360-degree product views, and ‘one click buy’.

ARitize™ 3D/AR Advertising Platform:
Launched in Q1 2020 the ad platform will be the industry’s first end-to-end solution whereby the company will leverage its 3D asset creation into 3D/AR ads. In 2019, according to IDC, global advertising spend will be about $725 billion.

ARitize™ Hollywood Studios
: The studio is in development producing immersive content using 360 video, and augmented reality as the primary display platform.

To learn more, please follow us on Twitter, YouTube, Instagram, LinkedIn, and Facebook, or visit our website: https://www.nextechar.com.

On behalf of the Board of NexTech AR Solutions Corp.

“Evan Gappelberg” CEO and Director

For further information, please contact:

Evan Gappelberg
Chief Executive Officer
[email protected]   

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be”, “looking forward” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the Company increasing investors awareness are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause
the actual results, levels of activity, performance or achievements of NexTech to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. NexTech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.